Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533966 | 0.79 | AURKA (0.37) | AURKAADORA3AURKB | |
| SCHEMBL8426788 | 0.79 | AURKA (0.35) | AURKAADORA3MAPKAPK5 | |
| SCHEMBL8429587 | 0.78 | ADORA3 (0.38) | AURKAADORA3AURKBFLT3MAPKAPK5 | |
| SCHEMBL8427744 | 0.77 | MAPKAPK5 (0.38) | AURKAADORA3SYKMAPKAPK5 | |
| SCHEMBL14533910 | 0.76 | AURKA (0.35) | AURKAADORA3AURKB | |
| SCHEMBL8426673 | 0.76 | AURKA (0.56) | AURKAADORA3SYKAURKB | |
| SCHEMBL8427741 | 0.76 | BRD4 (0.39) | ADORA3SYK | |
| SCHEMBL14534281 | 0.75 | LRRK2 (0.40) | — | |
| SCHEMBL8241173 | 0.75 | AURKA (0.60) | AURKAAURKBFLT3MAPKAPK5 | |
| SCHEMBL8429895 | 0.74 | PAK4 (0.42) | AURKAADORA3AURKBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | AURKA 40/4885ADORA3 2455/4885SYK 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.